Evidence map›Paper›PMID 24348761›Full record

ArticleExperimental and therapeutic medicine2014

Pyrrolidine dithiocarbamate (PDTC) inhibits the overexpression of MCP-1 and attenuates microglial activation in the hippocampus of a pilocarpine-induced status epilepticus rat model.

Rilang Lv, Xiaoyun Xu, Zheng Luo, Nan Shen, Feng Wang, Yongbo Zhao

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Long-Term Intake ofEvidence-based complementary and alternative medicine : eCAM · 2017
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rilang LvDepartment of Neurology, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai 200210, P.R. China.
Xiaoyun XuDepartment of Neurology, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai 200210, P.R. China ; Department of Neurology, Shanghai Pudong New Area Zhoupu Hospital, Shanghai 201318, P.R. China.
Zheng LuoDepartment of Neurology, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai 200210, P.R. China.
Nan ShenDepartment of Neurology, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai 200210, P.R. China.
Feng WangDepartment of Neurology, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, P.R. China.
Yongbo ZhaoDepartment of Neurology, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, P.R. China.
Shanghai East Hospital · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the effects of pyrrolidine dithiocarbamate (PDTC) on MCP-1 expression and microglial activation in the hippocampus of a rat model of pilocarpine (PILO)-induced status epilepticus (SE). Moreover, seizure susceptibility, frequency and severity as well as brain damage were analyzed and changes in behavior were recorded. Chemokine MCP-1 expression and microglial activation were detected by immunohistochemistry (IHC). Fluoro-Jade C (FJC) and NeuN staining were used for the evaluation of tissue damage. Our results showed that although SE resulted in the upregulation of MCP-1 and microglial activation in the rat hippocampus 24 h after seizure onset, pretreatment with PDTC significantly inhibited the MCP-1 overexpression and attenuated the microglial activation. These effects were accompanied by neurodegenerative amelioration. To the best of our knowledge, these findings indicated for the first time that the activation of the nuclear factor-κB (NF-κB) pathway may contribute to MCP-1 upregulation and microglial activation in the context of epilepsy. PDTC was also shown to exert anticonvulsant activity and to have a neuroprotective effect on the hippocampal CA1 and CA3 regions, potentially through attenuating microglial activation.

Indexed as

epilepsyhippocampusMCP-1 (CCL2)nuclear factor-κBpilocarpine-induced status epilepticus rat modelpyrrolidine dithiocarbamate

Identifiers

PMID24348761
PMCPMC3861516
OpenAlexW2038720330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.